Stem cell bond issue has narrow lead in poll
By Associated Press,
Associated Press
| 10. 11. 2004
A controversial measure that would provide $3 billion in state bond money to pay for human embryonic stem cell research holds a narrow margin of support among voters, according to a new Field Poll.
Proposition 71, designed to get around the Bush administration's funding limits on such research, would authorize the state to sell bonds to provide annual payments of about $300 million to scientists and companies doing stem cell research.
The poll found that 46 percent of likely voters support the idea with 39 percent opposed and 15 percent undecided. The margin of error was 4.3 percentage points.
The numbers are a slight improvement from an August poll that found 45 percent supported the bond measure to 42 percent opposed.
Supporters of the proposition -- including a coalition of influential Democratic donors and several Silicon Valley tycoons -- have raised more than $12 million for the campaign and are running TV ads.
The Field Poll found that half of those surveyed said they had seen or heard something about the initiative -- an improvement since August of 10 percentage...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
